Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application (Q34117986)

31 July 2017

1 reference

title

Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application (English)

1 reference

31 July 2017

E Garaci

1

1 reference

31 July 2017

F Pica

series ordinal

2

1 reference

31 July 2017

G Rasi

series ordinal

3

1 reference

31 July 2017

C Favalli

series ordinal

4

1 reference

31 July 2017

publication date

1 December 2000

1 reference

International Journal of Immunopharmacology

31 July 2017

published in

1 reference

31 July 2017

volume

22

1 reference

31 July 2017

issue

12

1 reference

31 July 2017

page(s)

1067-1076

1 reference

Thymosin alpha 1 exerts protective effect against the 5-FU induced bone marrow toxicity

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900075-8

7 January 2021

Production of human B and T cell growth factors is enhanced by thymic hormones

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900075-8

7 January 2021

Thymosin Treatment Modulates Production of Interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900075-8

7 January 2021

Induction and augmentation of mitogen-induced immune interferon production in human peripheral blood lymphocytes by Nα-desacetylthymosin αl

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900075-8

7 January 2021

Modulation of interleukin 2 receptor expression on normal human lymphocytes by thymic hormones

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900075-8

7 January 2021

Characterization of the immunoregulatory properties of thymosin alpha 1 on interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900075-8

7 January 2021

Thymosin alpha 1 modulates the expression of high affinity interleukin-2 receptors on normal human lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900075-8

7 January 2021

Immunotherapy with natural interleukins and/or thymosin alpha 1 potently augments T-lymphocyte responses of hydrocortisone-treated aged mice

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900075-8

7 January 2021

Thymosin-alpha1 stimulates maturation of CD34+ stem cells into CD3+4+ cells in an in vitro thymic epithelia organ coculture model

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900075-8

7 January 2021

Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900075-8

7 January 2021

Modulation of natural killer activity by thymosin alpha 1 and interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900075-8

7 January 2021

Synergistic effect of thymosin alpha 1 and alpha beta-interferon on NK activity in tumor-bearing mice

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900075-8

7 January 2021

Combination treatment using thymosin alpha 1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900075-8

7 January 2021

Combination therapy with thymosin alpha 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900075-8

7 January 2021

Immunotherapy of cancer using interleukin 2: current status and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900075-8

7 January 2021

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900075-8

7 January 2021

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900075-8

7 January 2021

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900075-8

7 January 2021

Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900075-8

7 January 2021

Thymosin alpha 1 potentiates interleukin 2-induced cytotoxic activity in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900075-8

7 January 2021

Antitumor effect of thymosin alpha 1/interleukin-2 or thymosin alpha 1/interferon alpha,beta following cyclophosphamide in mice injected with highly metastatic Friend erythroleukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900075-8

7 January 2021

Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900075-8

7 January 2021

The interferons. Mechanisms of action and clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900075-8

7 January 2021

IFN-beta partially counteracts inhibition of natural killer activity induced by some antitumor agents

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900075-8

7 January 2021

HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900075-8

7 January 2021

IFN-alpha 1 gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57BL/6 mice

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900075-8

7 January 2021

Biochemotherapy with thymosin alpha 1, interleukin-2 and dacarbazine in patients with metastatic melanoma: clinical and immunological effects

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900075-8

7 January 2021

Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900075-8

7 January 2021

10.1016/S0192-0561(00)00075-8

Identifiers

DOI

1 reference

31 July 2017

1 reference